WuXi AppTec was founded in 2000 in Wuxi, Jiangsu Province. Provide comprehensive and integrated new drug development and production services for the global biomedical industry. WuXi AppTec has a total of 4 founders, Li Ge, Liu Xiaozhong and Zhang Zhaohui, and Zhao Ning joined later. Dr. Ye Ge, a native of Pingyang, Wenzhou, Zhejiang, was born in Beijing, majoring in chemistry at Peking University and ph.D. in organic chemistry from Columbia University. He founded Pharmacopeia with his supervisor and several postdoctoral classmates, and successfully landed on the NASDAQ in one year.
In 2000, WuXi AppTec was established in Wuxi, Jiangsu Province, with an operations center in Shanghai.
In 2001, synthetic chemistry services were launched.
In 2003, the process research and development services were carried out.
In 2004, we carried out R&D production services.
In 2005, bioanalytical services were launched.
In 2006, we carried out biological new drug development and process research and development services.
In 2007, toxicology and formulation services were launched. The Tianjin branch was put into operation, which was a first-class chemical base in China at that time. Successfully landed on the New York Stock Exchange. The "WuXi AppTec Biochemistry Research Award" was established to promote scientific and technological progress and industrial development in related fields such as biochemistry in China.
In 2008, it acquired AppTec Laboratory Services Co., Ltd. in the United States, and the company's English name was changed to WuXi AppTec.
In 2009, the suzhou safety evaluation center was completed as the main base for WuXi AppTec to carry out toxicology services.
In 2010, a large-scale production base of Hequan Pharmaceutical was established in Jinshan.
In 2011, Jinshi Jiecheng Company was acquired to establish clinical research and development and registration services.
In 2012, Wuxi R&D and production base was officially put into operation. The Wuhan branch was officially put into operation, becoming the core of the company's strategy of the midwest base.
In 2014, a new production plant was built in Philadelphia, USA, to develop and produce CAR-T and related cancer immune cell therapies. Acquired The United States Metalno Corporation and fully expanded its laboratory testing business.
In 2015, Hequan Pharmaceutical was successfully listed on the New Third Board. Launched medical device testing services in China.
In 2016, it acquired Crelux, a German drug discovery service provider, to establish and expand its R&D facilities in the European region. Subsidiary Hequan Pharmaceutical Changzhou integrated R&D and cGMP production base were officially put into operation.
In 2017, the High-end Therapeutics Division in the United States was established, focusing on the development of treatment businesses such as cell and gene therapy. Acquired Huiyuan Biologics to further consolidate the platform biology research and development capabilities and scale. Acquisition of ResearchPoint Global to further expand globally integrated clinical development services.
In 2018, the Life and Health Industrial Park settled in Chengdu. Wuxi WuXi AppTec New Drug Development Co., Ltd. is listed on the Shanghai Stock Exchange, and WuXi Biologics is listed on the Hong Kong Stock Exchange.
In 2019, the first WuXi AppTec Health Industry Forum was successfully held in Shanghai. Acquired Pharmace in the United States to expand the capabilities of clinical research data statistical analysis services.
In 2020, Chengdu R&D Center was officially put into operation.
Throughout the development history of WuXi AppTec, it is a process of continuously expanding the service capabilities and boundaries related to drug research and development in the early stage, continuously acquiring and expanding the market in the later stage, and achieving a sharp increase in wealth through the spin-off and listing of three companies. From the research and development of small molecule chemical drugs to the research and development of biological drugs and medical devices, the business covers cro to CMO, CDMO drug research and development, and the whole industrial chain of foundry production, and its positioning of itself is to make the world have no difficult drugs and incurable diseases. It plays an important role in helping global pharmaceutical companies accelerate the development and manufacturing of new drugs.
In the field of contract research organization CRO (Contract Research Organization), according to the industrial chain, it is divided into two categories: pre-clinical research (Clinical Trial) and clinical research (Clinical Trial). The former is R&D outsourcing, and the latter is test verification outsourcing. The CMO (Contract manufacturing organization) is custom manufacturing, and the CDMO (Contract development and manufacturing organization) is custom development and production. Bias towards the production side. WuXi AppTec has been involved in R&D outsourcing to production outsourcing.
Tigermed, which was shared earlier, is concentrated in the CRO field, while WuXi AppTec's industrial reach is more extensive. This has also become a unique advantage of WuXi AppTec and formed a leading pattern in the pan-drug R&D service industry.
Dr. Li Ge once said that what I most hope to see is that in the near future, a person, an idea, a piece of paper, a pen, a credit card, can carry out new drug research and development on WuXi AppTec's empowerment platform. He just needs to take a piece of paper, draw the molecular structure he wants to make, take a picture of his mobile phone and send it to us, and we can help achieve it.
Doing the right thing and doing it well is WuXi AppTec's credo.
Let's look at Zhao Ning again.
Zhao Ning, a post-60s native of Wenzhou, Zhejiang, majored in chemistry at Peking University, Ph.D. in organic chemistry at Columbia University, and worked for Bristol-Myers Squibb, Pharmacopeia, and Wyeth Pharmaceuticals (now Pfizer). WuXi AppTec Vice President of Human Resources, Founder Ye Ge's PhD classmate and wife. There is very little information about Zhao Ning, but the same is a bully, the same as an alumnus, and later became the golden partner of the husband and wife in the business world, with a difference between inside and outside, and an orderly division of labor. Coupled with the long-tail effect of foreign and Chinese small and medium-sized pharmaceutical companies, the liberalization of China's pharmaceutical research and development policies are all favorable to the development of WuXi AppTec.
As the first company in China to engage in ORC services, WuXi AppTec can be described as a first opportunity. What do you think?
![Zhao Ningyu, screenwriter of "King Kong Chuan": People who said that Tang Guoqiang played Chairman Mao was not like now say that he is the most like[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)